AU693628B2 - Use of 3,4-diphenylchromans - Google Patents

Use of 3,4-diphenylchromans

Info

Publication number
AU693628B2
AU693628B2 AU43293/96A AU4329396A AU693628B2 AU 693628 B2 AU693628 B2 AU 693628B2 AU 43293/96 A AU43293/96 A AU 43293/96A AU 4329396 A AU4329396 A AU 4329396A AU 693628 B2 AU693628 B2 AU 693628B2
Authority
AU
Australia
Prior art keywords
treatment
use according
pharmaceutically acceptable
lower alkyl
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU43293/96A
Other languages
English (en)
Other versions
AU4329396A (en
Inventor
Martin William Edwards
Birgitte Hjort Guldhammer
Ved Prakash Kamboj
Niels Korsgaard
Virender Mohan Labroo
James Robertson Piggott
Suprabhat Ray
Michael Shalmi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU4329396A publication Critical patent/AU4329396A/en
Application granted granted Critical
Publication of AU693628B2 publication Critical patent/AU693628B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU43293/96A 1995-01-13 1996-01-10 Use of 3,4-diphenylchromans Ceased AU693628B2 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
DK45/95 1995-01-13
DK4795 1995-01-13
DK4695 1995-01-13
DK48/95 1995-01-13
DK4895 1995-01-13
DK44/95 1995-01-13
DK4495 1995-01-13
DK4595 1995-01-13
DK47/95 1995-01-13
DK46/95 1995-01-13
DK772/95 1995-06-30
DK76995 1995-06-30
DK77095 1995-06-30
DK771/95 1995-06-30
DK770/95 1995-06-30
DK76895 1995-06-30
DK768/95 1995-06-30
DK769/95 1995-06-30
DK77295 1995-06-30
DK77195 1995-06-30
PCT/DK1996/000015 WO1996021444A1 (en) 1995-01-13 1996-01-10 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of gynaecological disorders

Publications (2)

Publication Number Publication Date
AU4329396A AU4329396A (en) 1996-07-31
AU693628B2 true AU693628B2 (en) 1998-07-02

Family

ID=27579214

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43293/96A Ceased AU693628B2 (en) 1995-01-13 1996-01-10 Use of 3,4-diphenylchromans

Country Status (11)

Country Link
EP (1) EP0804190A1 (no)
JP (1) JPH10511962A (no)
CN (1) CN1168096A (no)
AU (1) AU693628B2 (no)
CA (1) CA2208861A1 (no)
CZ (1) CZ212297A3 (no)
HU (1) HUP9702244A3 (no)
IL (1) IL116746A0 (no)
MX (1) MX9705219A (no)
NO (1) NO973243L (no)
WO (1) WO1996021444A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270056A1 (en) * 1996-10-28 1998-05-07 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA979644B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
US5994390A (en) * 1996-10-28 1999-11-30 Novo Nordisk Trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
JP2001502704A (ja) * 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は処置において有用な新規ｃｉｓ―３，４―クロマン誘導体の新規の（―）―鏡像異性体
US6316494B1 (en) 1996-10-28 2001-11-13 Novo Nordisk A/S cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO1998018772A1 (en) * 1996-10-28 1998-05-07 Novo Nordisk A/S NOVEL cis-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES
US5985306A (en) * 1996-10-28 1999-11-16 Novo Nordisk A/S (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
US5958967A (en) * 1996-10-28 1999-09-28 Novo Nordisk A/S Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ATE229519T1 (de) * 1996-10-28 2002-12-15 Novo Nordisk As Neue cis-3,4-chromanderivate zur vorbeugung oder behandlung von oestrogenbezogenen krankheiten oder syndromen
US5919817A (en) * 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
EP0937059A1 (en) * 1996-10-28 1999-08-25 Novo Nordisk A/S NOVEL $i(TRANS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES
US6043269A (en) * 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
DE69717843T2 (de) * 1996-10-28 2003-09-25 Novo Nordisk A/S, Bagsvaerd Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
AU4700097A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA979648B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
JP4896335B2 (ja) 2000-03-01 2012-03-14 ナームローゼ・フエンノートチヤツプ・オルガノン エストロゲン化合物としてのクロマン誘導体
ATE532777T1 (de) 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
JP6013349B2 (ja) 2010-11-01 2016-10-25 メイ ファーマ, インク.Mei Pharma, Inc. 癌の処置のためのイソフラボノイド化合物および方法
AU2015213484B2 (en) 2014-02-07 2015-11-05 Kazia Therapeutics Limited Functionalised benzopyran compounds and use thereof
ES2877712T3 (es) 2015-02-02 2021-11-17 Mei Pharma Inc Terapias combinadas para su uso en el tratamiento del cáncer de mama

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672412A2 (en) * 1994-02-18 1995-09-20 Eli Lilly And Company Use of 3,4-diphenyl chromans for the manufacture of a medicament for lowering cholesterol levels

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672412A2 (en) * 1994-02-18 1995-09-20 Eli Lilly And Company Use of 3,4-diphenyl chromans for the manufacture of a medicament for lowering cholesterol levels

Also Published As

Publication number Publication date
HUP9702244A3 (en) 1999-12-28
JPH10511962A (ja) 1998-11-17
MX9705219A (es) 1997-10-31
HUP9877967A2 (en) 1998-12-28
EP0804190A1 (en) 1997-11-05
NO973243D0 (no) 1997-07-11
CZ212297A3 (en) 1997-11-12
WO1996021444A1 (en) 1996-07-18
CA2208861A1 (en) 1996-07-18
CN1168096A (zh) 1997-12-17
NO973243L (no) 1997-07-11
AU4329396A (en) 1996-07-31
IL116746A0 (en) 1996-05-14

Similar Documents

Publication Publication Date Title
AU693628B2 (en) Use of 3,4-diphenylchromans
US5726202A (en) Benign prostatic hypertrophy
US5883118A (en) Prostatic carcinoma
US5747059A (en) Atrophy of skin/mucous membrane
EP0873120A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
CA2208859A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment
US5919812A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia
WO1996022092A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
US5886021A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
WO1998033499A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women
US5780502A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
MXPA97005219A (en) Use of 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment of profilaxis of disorders ginecologi
WO1998033500A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment
EP0954307A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
KR19980701383A (ko) 부인병 질환의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia)
EP0921797A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for lowering intraocular pressure
MXPA97005218A (es) Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis de ginecomastia idiopatica o fisiologica
KR19980701384A (ko) 측발성 또는 생리적 여성형유방의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용
MXPA97005379A (en) Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for treatment or profilaxis vasodilatad
MXPA97005378A (en) Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of the obesi

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired